14 September 2015
A new report by visiongain predicts that the world infusion pumps market will reach $8.09bn in 2015. This forecast and others appear in Infusion Pumps Market: Prospects for Leading Companies 2015-2025, published in October 2015. Visiongain is a business information provider based in London, UK.
Infusion pumps deliver fluids, nutrients, and medications such as antibiotics, chemotherapy drugs, and pain relievers, into a patient’s body in controlled amounts. Generally, they are used intravenously, but arterial, subcutaneous (beneath the skin), and epidural (just within the surface of the central nervous system) infusions are occasionally used. The leading segment within the market is the insulin infusion segment, driven by an increasing incidence of diabetes. While the number of diabetes patients is only set to grow, the infusion pumps market has remained significantly under-penetrated, leading visiongain to believe there will be a number of opportunities for success in the next decade. We estimate the total infusion pumps market worth to reach $8.09bn in 2015.
Maria Kercheva, a pharmaceutical and medical devices industry analyst in visiongain, said: “In 2013, diabetes affected 381.8million people while 175 million remained undiagnosed. Furthermore, it was estimated that around 10% of Type I and a very small proportion of Type II diabetics in the US use insulin infusion pumps as their main source of insulin. Those figures, combined with an increasing pump adoption, prevalence of chronic diseases and unmet needs for technological advances will serve as market growth drivers. A strong pipeline of investigational pumps and other systems is discussed in this report and will undoubtedly change the infusion pumps landscape once commercialised. Additionally, opportunities for medical devices companies continue arising, as patients demand safer and more-reliable treatment options. The next decade will see advances in all sub-segments of the market and will create opportunities for companies that are ready to offer technological advances in the field.”
Included in the report is a lengthy discussion of the strengths and weakness of the field of infusion pumps, as well as the opportunities and threats facing developers. The report includes a forecast of the global infusion pumps market through to 2025, as well as forecasts for three submarkets:
• Insulin pumps,
• Enteral feeding pumps
• Other pumps (a grouped category inclusive of chemotherapy pumps and PCA infusion pumps)
National markets are also discussed, with forecasts to 2025 provided for the US, EU5 (Germany, UK, France, Italy and Spain), Japan, China, India, Brazil, Russia and South Korea.
This independent, 206-page report guarantees you will remain better informed than your competition. With 128 tables and figures examining the infusion pumps market space, the report gives you a visual, one-stop breakdown of your market. In addition, this report provides analysis of competing technologies, with forecasts to 2025 for the global drug delivery technologies market and the following submarkets:
• Oral drug delivery
• Inhalation drug delivery
• Injectable/implantable drug delivery
• Transdermal drug delivery
• Ocular drug delivery
• Nasal drug delivery
Infusion Pumps Market: Prospects for Leading Companies 2015-2025 adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on firstname.lastname@example.org
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.